康寧傑瑞製藥(09966.HK)四項新藥臨床試驗申請獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康寧傑瑞製藥(09966.HK)四項新藥臨床試驗申請獲批

阿思達克 02-20 08:26

康寧傑瑞製藥(09966.HK)公布，集團針對程式性死亡配體/細胞毒性淋巴細胞相關蛋白4(「PD-L1/CTLA-4」)雙特異性抗體及人表皮生長因數受體2(「HER2」)雙特異性抗體的四項新藥臨床試驗申請，近日已獲中國國家藥品監督管理局藥品審評中心受理。(sw/w)~ 阿思達克財經新聞網址: www.aastocks.com

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康寧傑瑞製藥(09966.HK)四項新藥臨床試驗申請獲批

Services

About Us

Agreement Statement